Smith+Nephew (NYSE:SNN) today announced that it has expanded the indications on its Cori Surgical System to include total hip arthroplasty.
The London-based company previously designed the handheld robotic solution for total knee arthroplasty. The new indication with RI.Hip Navigation is designed to help maximize accuracy and reproducibility by delivering patient-specific component alignment to THA, according to the company.
“The addition of RI.Hip Navigation on the Cori System further strengthens Smith+Nephew’s Real Intelligence digital ecosystem and underscores our commitment to advancing clinical outcomes in total hip arthroplasty,” Randy Kilburn, EVP and general manager of reconstruction, robotics and digital surgery, said in a news release. “We look forward to offering the possibility of further improving patient outcomes and satisfaction to a broader surgeon community with the rapidly expanding adoption of our Cori Surgical System.”
Smith+Nephew’s RI.Hip Navigation recently received FDA 510(k) clearance for use in the Cori system. The company said software installations will start immediately for a limited number of hospitals and ambulatory surgery centers in the U.S. with a broad commercial availability later this year. The new indication will be introduced in European and Asia Pacific markets once regulatory authorizations are finalized.